Antitumoral activity of interferon-γ involved in impaired immune function in cancer patients

被引:80
作者
Brandacher, Gerald
Winkler, Christiana
Schroecksnadel, Katharina
Margreiter, Ralinund
Fuchs, Dietmar
机构
[1] Univ Innsbruck, Bioctr, Div Biol Chem, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, Tyrolean Canc Res Inst, Dept Gen & Transplant Surg, A-6020 Innsbruck, Austria
[3] Ludwig Boltzmann Inst AIDS Res, Innsbruck, Austria
关键词
interferon-gamma; cancer; immunodeficiency; indoleamine 2,3-dioxygenase;
D O I
10.2174/138920006778017768
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
insufficient itrurrunosurveillance is air important aspect in early tumorgenesis and in the pathoagenesis of malignant disease. In the later course of cancer, the development of immunodeficiency is considered the major reason for disease progression and death. Within the anti-tumoral host defense reaction. Th1-type cytokine interferon-gamma (IFN-gamma) is of particular relevance. IFN-gamma stimulates several anti-proliferative and thus tumoricidal biochemical pathways in macrophages and other cells and also in tumor cell lines. These include inducible nitric oxide synthase, indoleamine (2, 3)dioxygenase, an enzyme degrading the essential amino acid tryptophan, and the production of reactive oxygen species and neopterin in human macrophages and dendritic cells. Although the anti-proliferative strategy of the immune system aims to inhibit the growth of malignant cells, it can also affect T-cell response and thus contribute to the development of immunodeficiency. Accelerated degradation of tryptophan and increased production of neopterin were found to parallel the course of malignant diseases. Moreover, a higher degree of these metabolic changes characterizes poor prognosis and is associated with the development of anemia, weight loss and depressive mood in patients. Available data suggest that immunodeficiency in cancer patients may develop as a long-term side-effect of the antiproliferative and pro-apoptotic mechanisms elicited within Th1-type immune response, and enhanced production of pro-inflammatory cytokine IFN-gamma seems to be critically involved.
引用
收藏
页码:599 / 612
页数:14
相关论文
共 138 条
  • [1] INHIBITION OF TUMOR-CELL GROWTH BY INTERFERON-GAMMA IS MEDIATED BY 2 DISTINCT MECHANISMS DEPENDENT UPON OXYGEN-TENSION - INDUCTION OF TRYPTOPHAN DEGRADATION AND DEPLETION OF INTRACELLULAR NICOTINAMIDE ADENINE-DINUCLEOTIDE
    AUNE, TM
    POGUE, SL
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (03) : 863 - 875
  • [2] Immunobiology of dendritic cells
    Banchereau, J
    Briere, F
    Caux, C
    Davoust, J
    Lebecque, S
    Liu, YT
    Pulendran, B
    Palucka, K
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 : 767 - +
  • [3] Bender D.A., 1986, PROGR TRYPTOPHAN SER, P159
  • [4] INTERFERON-GAMMA, MORE OF A CACHECTIN THAN TUMOR-NECROSIS-FACTOR
    BILLIAU, A
    MATTHYS, P
    [J]. CYTOKINE, 1992, 4 (04) : 259 - 263
  • [5] NEUROPEPTIDE-Y IN HYPOTHALAMIC PARAVENTRICULAR NUCLEUS - A CENTER COORDINATING ENERGY-METABOLISM
    BILLINGTON, CJ
    BRIGGS, JE
    HARKER, S
    GRACE, M
    LEVINE, AS
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (06): : R1765 - R1770
  • [6] Interferons α and β as immune regulators -: A new look
    Biron, CA
    [J]. IMMUNITY, 2001, 14 (06) : 661 - 664
  • [7] Human tumor antigens recognized by T lymphocytes
    Boon, T
    vanderBruggen, P
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) : 725 - 729
  • [8] Second-generation interferons for cancer: clinical targets
    Borden, EC
    Lindner, D
    Dreicer, R
    Hussein, M
    Peereboom, D
    [J]. SEMINARS IN CANCER BIOLOGY, 2000, 10 (02) : 125 - 144
  • [9] GENETIC MECHANISMS IN TUMOR INITIATION AND PROGRESSION .10. THE RAS GENE FAMILY AND HUMAN CARCINOGENESIS
    BOS, JL
    [J]. MUTATION RESEARCH, 1988, 195 (03): : 255 - 271
  • [10] Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:: Effect on tumor-infiltrating T cells
    Brandacher, G
    Perathoner, A
    Ladurner, R
    Schneeberger, S
    Obrist, P
    Winkler, C
    Werner, ER
    Werner-Felmayer, G
    Weiss, HG
    Göbel, G
    Margreiter, R
    Königsrainer, A
    Fuchs, D
    Amberger, A
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1144 - 1151